We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J
Read MoreHide Full Article
Evotec SE (EVO - Free Report) announced that it has entered into a drug discovery collaboration deal with Janssen Pharmaceutical NV, a wholly owned subsidiary of Johnson & Johnson (JNJ - Free Report) .
According to the deal, Evotec’s innovative TargetAlloMod platforms will be used to develop and discover first-in-class novel mode of action therapeutic candidates to provide innovative treatment options for patients.
The above agreement was facilitated by Johnson & Johnson Innovation.
Evotec and Janssen will together screen the identified targets and collaborate with hit identification and lead optimization for attractive chemical assets by leveraging Evotec’s end-to-end integrated drug discovery and development platform.
Evotec will get research funding from J&J’s Janssen. The company is also eligible to receive milestone payments of around € 210 million per project as well as tiered royalties if a product is commercialized from the above collaboration.
Shares of Evotec lost 3.8% on Tuesday as investors probably jeered the news. The stock has plunged 50.8% so far this year compared with the industry’s decrease of 28.7%.
Image Source: Zacks Investment Research
The above partnership deal will leverage Evotec’s proprietary platform capabilities in the field of protein homeostasis.
In a separate press release, Evotec’s partner, Exscientia (EXAI - Free Report) , announced top-line data from an early-stage study evaluating its highly selective A2A receptor antagonist, EXS-21546, in healthy volunteers.
EXS-21546 is co-invented and developed by Exscientia and Evotec.
Data from the phase Ia healthy volunteer study confirmed that EXS-21546 is a highly potent and selective A2AR antagonist with low central nervous system or CNS exposure.
The phase Ia study was a three-part dose-finding study that evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses and multiple ascending doses of EXS-21546.
One primary goal of the study was to determine the optimal starting dose of EXS-21546 for the phase Ib/II study in cancer patients.
Supported by these data, Exscientia plans to initiate a phase Ib/II study on EXS-21546 in patients with solid tumors exhibiting high adenosine signatures in the second half of 2022.
The Zacks Consensus Estimate for Galmed Pharmaceuticals’ loss per share has narrowed 37.9% for 2022 and 53.8% for 2023 in the past 60 days.
Earnings of Galmed Pharmaceuticals have surpassed estimates in each of the trailing three quarters. GLMD delivered an earnings surprise of 23.09%, on average.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J
Evotec SE (EVO - Free Report) announced that it has entered into a drug discovery collaboration deal with Janssen Pharmaceutical NV, a wholly owned subsidiary of Johnson & Johnson (JNJ - Free Report) .
According to the deal, Evotec’s innovative TargetAlloMod platforms will be used to develop and discover first-in-class novel mode of action therapeutic candidates to provide innovative treatment options for patients.
The above agreement was facilitated by Johnson & Johnson Innovation.
Evotec and Janssen will together screen the identified targets and collaborate with hit identification and lead optimization for attractive chemical assets by leveraging Evotec’s end-to-end integrated drug discovery and development platform.
Evotec will get research funding from J&J’s Janssen. The company is also eligible to receive milestone payments of around € 210 million per project as well as tiered royalties if a product is commercialized from the above collaboration.
Shares of Evotec lost 3.8% on Tuesday as investors probably jeered the news. The stock has plunged 50.8% so far this year compared with the industry’s decrease of 28.7%.
Image Source: Zacks Investment Research
The above partnership deal will leverage Evotec’s proprietary platform capabilities in the field of protein homeostasis.
In a separate press release, Evotec’s partner, Exscientia (EXAI - Free Report) , announced top-line data from an early-stage study evaluating its highly selective A2A receptor antagonist, EXS-21546, in healthy volunteers.
EXS-21546 is co-invented and developed by Exscientia and Evotec.
Data from the phase Ia healthy volunteer study confirmed that EXS-21546 is a highly potent and selective A2AR antagonist with low central nervous system or CNS exposure.
The phase Ia study was a three-part dose-finding study that evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses and multiple ascending doses of EXS-21546.
One primary goal of the study was to determine the optimal starting dose of EXS-21546 for the phase Ib/II study in cancer patients.
Supported by these data, Exscientia plans to initiate a phase Ib/II study on EXS-21546 in patients with solid tumors exhibiting high adenosine signatures in the second half of 2022.
Zacks Rank & Stock to Consider
Evotec currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the same sector is Galmed Pharmaceuticals Ltd. (GLMD - Free Report) , which has a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Galmed Pharmaceuticals’ loss per share has narrowed 37.9% for 2022 and 53.8% for 2023 in the past 60 days.
Earnings of Galmed Pharmaceuticals have surpassed estimates in each of the trailing three quarters. GLMD delivered an earnings surprise of 23.09%, on average.